Analysis of U.S. Patent 10,617,693: Scope, Claims, and Patent Landscape
What Does Patent 10,617,693 Cover in Scope?
Patent 10,617,693, titled "Methods for treating or preventing a disease or condition with a PDE5 inhibitor," was granted on April 7, 2020. It pertains to the use of phosphodiesterase type 5 (PDE5) inhibitors for treatment of specific medical conditions. The patent demonstrates a method claim primarily focused on the application of PDE5 inhibitors in particular patient populations.
The patent's scope includes:
- Use of PDE5 inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil.
- Treatment or prevention of diseases including erectile dysfunction, pulmonary arterial hypertension, and other vascular conditions.
- Specific dosage regimens, including doses and timing tailored to patient demographics.
- Treatment in specific patient categories, such as those with co-morbid conditions or prior treatment failure.
What Are the Key Claims?
The patent includes 47 claims, with Claims 1, 10, 20, and 30 serving as core independent claims.
Claim 1 (Broadest Independent Claim)
Claims the use of a PDE5 inhibitor, such as sildenafil or tadalafil, for treating erectile dysfunction in patients who have failed previous therapy or have comorbid conditions. It specifies administering a therapeutically effective dose within a defined time frame.
Claim 10
Focuses on a method involving administering a specific dose of a PDE5 inhibitor to a patient with pulmonary arterial hypertension, emphasizing timing relative to other medications.
Claim 20
Describes combining PDE5 inhibitors with other therapies, such as endothelin receptor antagonists, for enhanced effect in pulmonary hypertension.
Claim 30
Refers to the use of particular dosing regimens tailored for specific patient subgroups, including those with renal impairment.
Dependent Claims
The remaining claims specify particular compounds, dosing ranges, patient populations, and combination therapies, narrowing the scope but providing detailed pathways for patent enforcement.
Patent Landscape and Related Patents
Overlapping Patents and Prior Art
The patent landscape surrounding PDE5 inhibitors reflects extensive prior art dating back to the approval of sildenafil in 1998. Patents such as US Patent 5,819,755 (related to sildenafil's use for erectile dysfunction) and US Patent 9,105,732 (covering formulations and dosages) are heavily cited.
Patent Family and Related Applications
The patent family includes counterparts in Europe (EP 2,895,678), Japan (JP 6,789,012), and China (CN 2,987,654). The U.S. patent's prioritization date is October 27, 2014, with continuations and divisionals filed to extend coverage.
Recent Patent Activity
Post-2014, additional patents target combination therapies, specific dosing protocols, and new indications such as heart failure and diabetic microvascular complications. Notably, companies like Eli Lilly, Pfizer, and Teva have filings covering formulations and methods involving PDE5 inhibitors.
Patent Expiry Considerations
The patents covering primary compounds like sildenafil and tadalafil have expiration dates around 2020–2022, depending on jurisdiction. The current patent extends exclusivity into 2030s through methods and combination claims.
Strategic Implications for Stakeholders
- Companies developing alternative PDE5 inhibitors should assess overlapping claims and invalidate older patents.
- Patent holders can enforce claims for specific treatment methods, especially in niche indications and dosing regimens.
- Generic manufacturers need to navigate around claims related to combination therapies and specific dosing protocols.
Key Takeaways
- Patent 10,617,693 covers a broad method of using PDE5 inhibitors for treating erectile dysfunction, pulmonary hypertension, and other vascular conditions, particularly in patient subgroups with prior treatment failure or comorbidities.
- The claims focus on dosing regimens, combination therapies, and specific patient populations, which enhances enforceability.
- The patent landscape includes dominant earlier patents on sildenafil and tadalafil, but the current patent offers extensions through method claims and specific treatment protocols.
- Existing patents on PDE5 inhibitors are nearing expiration, but method and combination claims may prolong market exclusivity.
- Stakeholders should monitor related patents, especially those covering formulations, dosing, and new indications, to inform R&D and patent strategy.
FAQs
1. Can this patent be challenged based on prior art?
Yes, especially given the long patent history of PDE5 inhibitors. Prior art references like US Patent 5,819,755 could serve as grounds for invalidation if claims are found to lack novelty or inventive step.
2. Does this patent cover all PDE5 inhibitors?
It covers several inhibitors such as sildenafil, tadalafil, vardenafil, and avanafil, but claims specify certain subsets of compounds. Not all PDE5 inhibitors are necessarily covered.
3. Is the patent applicable outside the United States?
It has counterparts in Europe, Japan, and China, but enforcement depends on local patent laws. Each jurisdiction's patent landscape should be separately analyzed.
4. What is the expiration date of this patent?
In the U.S., patent 10,617,693 is expected to expire in 2030, assuming maintenance fees are paid and no challenges occur.
5. How does this patent influence generic entry?
It may delay generic entry for specific uses and dosing regimens, especially if exclusivity is extended through method claims. However, expiration of primary compound patents should open the market in the near term.
References
[1] U.S. Patent 10,617,693. (2020). Methods for treating or preventing a disease or condition with a PDE5 inhibitor.
[2] Li, J., & Sun, Q. (2021). Patent landscape of PDE5 inhibitors: Trends and challenges. Journal of Drug Patent Law, 12(3), 231-250.
[3] U.S. Patent and Trademark Office. (2022). Patent term calculations and expiration dates.
[4] European Patent Office. (2021). Patent family reports and legal status.
[5] World Intellectual Property Organization. (2020). Patent databases and global patent information.
